thymosin beta-4 fragment raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-12-30 and is reviewed periodically as new material appears.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
| Property | Value | Notes |
|---|---|---|
| Generic designation | Synthetic thymosin beta-4 N-terminal fragment | Peptide nomenclature varies by supplier |
| Peptide length | Approximately 17 amino acid residues | Reported length sometimes differs between sources |
| N-terminal modification | Acetyl group | Affects mass and chromatographic behaviour |
| Compound class | Small synthetic peptide | Not a small-molecule drug |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Naming is inconsistent in popular media |
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
The word chemistry comes from a modification during the Renaissance of the word alchemy, which referred to an earlier set of practices that encompassed elements of chemistry, metallurgy, philosophy, astrology, astronomy, mysticism, and medicine. Alchemy is often associated with the quest to turn lead or other base metals into gold, though alchemists were also interested in many of the questions of modern chemistry. The modern word alchemy in turn is derived from the Arabic word al-kīmīā (الكیمیاء). This may have Egyptian origins since al-kīmīā is derived from the Ancient Greek χημία, which is in turn derived from the word Kemet, which is the ancient name of Egypt in the Egyptian language. Alternately, al-kīmīā may derive from χημεία 'cast together'.
Since its premiere screening at the 2012 San Diego Comic-Con, Dredd received positive reviews from critics. On Rotten Tomatoes, the film has a rating of 80%, based on 171 reviews, with an average rating of 6.6/10. The website's critical consensus reads, "Fueled by bombastic violence and impressive special effects, rooted in self-satire and deadpan humor, Dredd 3D does a remarkable job of capturing its source material's gritty spirit." On Metacritic, the film has a score of 60 out of 100, based on 30 critics, indicating "mixed or average reviews". Audiences polled by CinemaScore gave the film a grade "B" on a scale of A+ to F. Some reviewers enjoyed its take on the titular character, with IGN praising it as a "character study". Urban's acting was frequently praised, particularly his ability to perform a characterless figure. Entertainment Weekly's Darren Franich enjoyed his "credibly wry performance using little more than his gravelly, imitation-[Clint] Eastwood voice—and his chin". Indiewire argued that with the film, he "continues to distinguish himself as a versatile performer who turns mimicry into emotional meaning". Variety's Geoff Berkshire wrote the actor "does a fine job embodying the more mythic qualities of Dredd as an upright law enforcer no lowlife would want to confront".
=== Infection === If a chronic wound becomes more painful this is a good indication that it is infected. A lack of pain however does not mean that it is not infected. Other methods of determination are less effective.
=== Nutritional displacement === The "empty calories" argument states that a diet high in added (or 'free') sugars will reduce consumption of foods that contain essential nutrients. This nutrient displacement occurs if sugar makes up more than 25% of daily energy intake, a proportion associated with poor diet quality and risk of obesity. Displacement may occur at lower levels of consumption.
Sources: en.wikipedia.org
== Kinetics == Stopped-flow spectrometry has been used to characterize the chemical mechanism and kinetics of AgNPs. Oxidative dissolution of AgNPs has been shown to be a first order reaction with respect to both silver and hydrogen peroxide and is independent of particle size.
=== EC 1.3.99 With unknown physiological acceptors === EC 1.3.99.1: The activity is included in EC 1.3.5.1, succinate dehydrogenase (quinone) EC 1.3.99.2: Now EC 1.3.8.1, butyryl-CoA dehydrogenase. EC 1.3.99.3: now EC 1.3.8.7, medium-chain acyl-CoA dehydrogenase, EC 1.3.8.8, long-chain acyl-CoA dehydrogenase and EC 1.3.8.9, very-long-chain acyl-CoA dehydrogenase EC 1.3.99.4: 3-oxosteroid 1-dehydrogenase EC 1.3.99.5: 3-oxo-5α-steroid 4-dehydrogenase (acceptor) EC 1.3.99.6: 3-oxo-5β-steroid 4-dehydrogenase EC 1.3.99.7: Now EC 1.3.8.6, glutaryl-CoA dehydrogenase EC 1.3.99.8: 2-furoyl-CoA dehydrogenase EC 1.3.99.9: Now EC 1.21.99.1, β-cyclopiazonate dehydrogenase EC 1.3.99.10: Now EC 1.3.8.4, isovaleryl-CoA dehydrogenase EC 1.3.99.11: transferred to EC 1.3.5.2, dihydroorotate dehydrogenase EC 1.3.99.12: Now classified as EC 1.3.8.5, 2-methyl-branched-chain-enoyl-CoA reductase EC 1.3.99.13: Now EC 1.3.8.8, long-chain-acyl-CoA dehydrogenase EC 1.3.99.14: cyclohexanone dehydrogenase EC 1.3.99.15: Now EC 1.3.7.8 EC 1.3.99.16: isoquinoline 1-oxidoreductase EC 1.3.99.17: quinoline 2-oxidoreductase EC 1.3.99.18: quinaldate 4-oxidoreductase EC 1.3.99.19: quinoline-4-carboxylate 2-oxidoreductase EC 1.3.99.20: Now EC 1.3.7.9, 4-hydroxybenzoyl-CoA reductase EC 1.3.99.21: Now EC 1.3.8.3, (R)-benzylsuccinyl-CoA dehydrogenase EC 1.3.99.22: Now EC 1.3.98.3, coproporphyrinogen dehydrogenase EC 1.3.99.23: all-trans-retinol 13,14-reductase EC 1.3.99.24: Now EC 1.3.8.16, 2-amino-4-deoxychorismate dehydrogenase EC 1.3.99.25: carvone reductase EC 1.3.99.26: all-trans-ζ-carotene desaturase EC 1.3.99.27: 1-hydroxycarotenoid 3,4-desaturase EC 1.3.99.28: phytoene desaturase (neurosporene-forming) EC 1.3.99.29: phytoene desaturase (zeta-carotene-forming) EC 1.3.99.30: phytoene desaturase (3,4-didehydrolycopene-forming) EC 1.3.99.31: phytoene desaturase (lycopene-forming) EC 1.3.99.32: glutaryl-CoA dehydrogenase (non-decarboxylating) EC 1.3.99.33: urocanate reductase EC 1.3.99.34: Now classified as EC 1.3.7.11, 2,3-bis-O-geranylgeranyl-sn-glycero-phospholipid reductase EC 1.3.99.35: Now EC 1.3.7.15, chlorophyllide a reductase * EC 1.3.99.36: cypemycin cysteine dehydrogenase (decarboxylating) EC 1.3.99.37: 1-hydroxy-2-isopentenylcarotenoid 3,4-desaturase EC 1.3.99.38: menaquinone-9 β-reductase EC 1.3.99.39: carotenoid φ-ring synthase EC 1.3.99.40: carotenoid χ-ring synthase
=== Other === Plantar fibromatosis is a relatively uncommon non-malignant thickening of the plantar fascia. Psoriatic arthritis is a type of inflammatory arthritis that may affect the plantar fascia. Plantar fascial rupture/tear is a relatively uncommon painful tearing of the plantar fascia. The tear can be full or partial.
Boron neutron capture therapeutics are pharmaceuticals intended for use to deliver boron-10 to cancerous cells as part of boron neutron capture therapy (BNCT). Boron-10 atoms strongly absorb neutrons to form a metastable state of boron-11, which undergoes α-decay. By accumulating boron-10 in cancerous cells and subjecting the tumor to neutron radiation, high-energy α particles are selectively delivered only to the target cells. This neutron bombardment results in the selective destruction of the tumor cells that the boron-10 was absorbed into. As of 2023, the technology is available in Japan only, and even there few implementations have been reported.
=== Recurring === Artemis Pebdani as Vice President Susan Ross Kate Burton as Sally Langston, former vice president George Newbern as Charlie Ricardo Chavira as Governor Francisco Vargas of Pennsylvania Mía Maestro as Elise Martin Gregg Henry as Hollis Doyle Norm Lewis as Senate Majority Leader Edison Davis Joelle Carter as Vanessa Moss Erica Shaffer as News Reporter Mackenzie Astin as Noah Baker John Prosky as Senator Gibson Rose Abdoo as Senator Linda Moskowitz Romy Rosemont as Patty Snell Paul Adelstein as Leo Bergen Brian Letscher as Tom Larsen Matthew Del Negro as Michael Ambruso Annabeth Gish as Lillian Forrester Danny Pino as Alejandro "Alex" Vargas
Sources: en.wikipedia.org
Jammu and Kashmir's economy is primarily services-based and agriculture-oriented. The gross domestic product of Jammu and Kashmir was estimated at ₹3.15 lakh crore (US$33 billion) in 2026–27. In the fiscal year 2023–2024, it is expected that Jammu and Kashmir's Gross Domestic Product (GDP) will exceed Rs 2.30 lakh crore, with a growth rate of 10%. Along with horticulture and agriculture, tourism is an important industry for Jammu and Kashmir, accounting for about 7% to its economy. The Kashmir Valley is known for its sericulture and cold-water fisheries. Wood from Kashmir is used to make high-quality cricket bats, popularly known as Kashmir Willow. Major agricultural exports from Jammu and Kashmir include apples, pears, cherries, plums, saffron and walnuts. The traditional Kashmiri handicrafts industry employs a large workforce of around 340 thousand artisans and has potential for producing export goods. Small-scale cottage industries include carpet weaving, silks, shawls, basketry, pottery, copper and silverware, papier-mâché and walnut wood. The horticulture sector is the next biggest source of income in the economy. The temperature of Jammu and Kashmir is also suited to floriculture and can support various species of flora.
==== William Henry Perkin’s mauveine ==== In 1856, 18 year old William Perkin accidentally discovered a dye he called mauve while trying to make quinine from the oxidation of allyl toluene in his home lab for his academic advisor and boss August Wilhelm von Hoffman. Hoffman reportedly referred to aniline, a major step in the synthesis, as his "first love," and was excited to have Perkin working with it. Perkin communicated with the textile industry, including Pullars of Perth, and John Hyde Christie, the chemist and general manager of John Orr Ewing and Co. about how to best market and produce his dye. He started production of aniline purple near London at the end of 1857 and remained the only producer for at least a few months. Perkin began making the intermediates for his dyes in-house, for example, nitro-benzene, expanding the scale of operations. By the summer of 1859, according to a satirical magazine Punch, London had fallen ill with 'the mauve measles'.
==== More essays on mass culture and literature ==== Adorno returned to Santa Monica to survey his prospects at the Hacker Foundation, as he would have forfeited his American citizenship by the middle of 1952 if he had continued to stay outside the country. While there, he wrote a content analysis of newspaper horoscopes (now collected in The Stars Down to Earth) and the essays "Television as Ideology" and "Prologue to Television"; even so, he was pleased when, at the end of ten months, he was enjoined to return as co-director of the Institute. Back in Frankfurt, he renewed his academic duties and, from 1952 to 1954, completed three essays: "Notes on Kafka," "Valéry Proust Museum," and an essay on Schoenberg following the composer's death, all of which were included in the 1955 essay collection Prisms. In response to the publication of Thomas Mann's The Black Swan, Adorno penned a long letter to the author, who subsequently approved its publication in the literary journal Akzente. A second collection of essays, Notes to Literature, appeared in 1958. After meeting Samuel Beckett while delivering a series of lectures in Paris the same year, Adorno set to work on "Trying to Understand Endgame," which, along with studies of Proust, Valéry, and Balzac, formed the central texts of the 1961 publication of the second volume of his Notes to Literature. Adorno's entrance into literary discussions continued in his June 1963 lecture at the annual conference of the Hölderlin Society.
=== Environmental and health hazards === Synthetic phenolic antioxidants (SPAs) and aminic antioxidants have potential human and environmental health hazards. SPAs are common in indoor dust, small air particles, sediment, sewage, river water and wastewater. They are synthesized from phenolic compounds and include 2,6-di-tert-butyl-4-methylphenol (BHT), 2,6-di-tert-butyl-p-benzoquinone (BHT-Q), 2,4-di-tert-butyl-phenol (DBP) and 3-tert-butyl-4-hydroxyanisole (BHA). BHT can cause hepatotoxicity and damage to the endocrine system and may increase the carcinogenicity of 1,1-dimethylhydrazine exposure. BHT-Q can cause DNA damage and mismatches through the cleavage process, generating superoxide radicals. DBP is toxic to marine life if exposed long-term. Phenolic antioxidants have low biodegradability, but they do not have severe toxicity toward aquatic organisms at low concentrations. Another type of antioxidant, diphenylamine (DPA), is commonly used in the production of commercial, industrial lubricants and rubber products and it also acts as an additive for automotive engine oils.
==== MeSH E05.595.402 – microscopy, electron ==== MeSH E05.595.402.150 – cryoelectron microscopy MeSH E05.595.402.250 – electron probe microanalysis MeSH E05.595.402.541 – microscopy, electron, scanning MeSH E05.595.402.580 – microscopy, electron, transmission MeSH E05.595.402.580.480 – microscopy, electron, scanning transmission MeSH E05.595.402.580.500 – microscopy, energy-filtering transmission electron MeSH E05.595.402.625 – microscopy, immunoelectron
Sources: en.wikipedia.org
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.
No. Thymosin beta-4 is the full-length protein of about forty-three amino acids, while the fragment covers only its beginning. The two are related but are not interchangeable in experimental or analytical terms.
The label is a catalogue designation that became common in non-technical discussion. Scientific papers usually refer to the fragment by sequence or as a thymosin beta-4 N-terminal peptide.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.